Susie M. Collins

932 total citations · 1 hit paper
16 papers, 522 citations indexed

About

Susie M. Collins is a scholar working on Physiology, Rheumatology and Molecular Biology. According to data from OpenAlex, Susie M. Collins has authored 16 papers receiving a total of 522 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Physiology, 10 papers in Rheumatology and 6 papers in Molecular Biology. Recurrent topics in Susie M. Collins's work include Nutrition and Health in Aging (11 papers), GDF15 and Related Biomarkers (10 papers) and Muscle Physiology and Disorders (3 papers). Susie M. Collins is often cited by papers focused on Nutrition and Health in Aging (11 papers), GDF15 and Related Biomarkers (10 papers) and Muscle Physiology and Disorders (3 papers). Susie M. Collins collaborates with scholars based in United Kingdom, United States and Belgium. Susie M. Collins's co-authors include Michelle I. Rossulek, Zahid Ali, Aoibhinn McDonnell, Richard P. Butt, Laura Iavarone, Simon Kirby, Shannon L. Lubaczewski, Magdalena Harrington, Roberto A. Calle and Danna M. Breen and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cell Metabolism.

In The Last Decade

Susie M. Collins

15 papers receiving 509 citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ponsegromab for the Treatment of Cancer Cachexia

2024 97 citations John D. Groarke, Jeffrey Crawford et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Susie M. Collins United Kingdom	9	286	175	147	71	66	16	522
Dong Dong Zhang China	13	156 0.5×	173 1.0×	21 0.1×	82 1.2×	87 1.3×	37	610
Sarah Farr Canada	13	135 0.5×	193 1.1×	37 0.3×	18 0.3×	23 0.3×	17	582
Wen‐Xie Xu China	13	181 0.6×	157 0.9×	11 0.1×	40 0.6×	58 0.9×	56	538
Sandra Labocha Germany	12	118 0.4×	180 1.0×	10 0.1×	67 0.9×	42 0.6×	18	428
Jana Bělobrádková Czechia	14	277 1.0×	63 0.4×	27 0.2×	9 0.1×	59 0.9×	19	607
Jianfang Liu China	11	51 0.2×	127 0.7×	17 0.1×	74 1.0×	55 0.8×	17	499
Elaine D. Por United States	13	164 0.6×	239 1.4×	12 0.1×	114 1.6×	112 1.7×	28	590
Felipe Henriques United States	15	431 1.5×	207 1.2×	18 0.1×	11 0.2×	19 0.3×	18	641
Frederick Mitchelson Australia	12	42 0.1×	190 1.1×	109 0.7×	28 0.4×	128 1.9×	20	513
Martin Schepelmann Austria	13	90 0.3×	160 0.9×	13 0.1×	24 0.3×	36 0.5×	25	408

Countries citing papers authored by Susie M. Collins

Since Specialization

Citations

This map shows the geographic impact of Susie M. Collins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susie M. Collins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susie M. Collins more than expected).

Fields of papers citing papers by Susie M. Collins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susie M. Collins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susie M. Collins. The network helps show where Susie M. Collins may publish in the future.

Co-authorship network of co-authors of Susie M. Collins

This figure shows the co-authorship network connecting the top 25 collaborators of Susie M. Collins. A scholar is included among the top collaborators of Susie M. Collins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susie M. Collins. Susie M. Collins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Crawford, Jennifer L., John D. Groarke, Susie M. Collins, et al.. (2024). LBA82 Efficacy and safety of ponsegromab, a first-in-class, monoclonal antibody inhibitor of growth differentiation factor 15, in patients with cancer cachexia: A randomized, placebo-controlled, phase II study. Annals of Oncology. 35. S1269–S1269.

Groarke, John D., Jeffrey Crawford, Susie M. Collins, et al.. (2024). Phase 2 study of the efficacy and safety of ponsegromab in patients with cancer cachexia: PROACC‐1 study design. Journal of Cachexia Sarcopenia and Muscle. 15(3). 1054–1061. 20 indexed citations

Bonomi, Philip, Sandra L. Gomez‐Perez, Palmi Shah, et al.. (2024). Frequency of weight and body composition increases in advanced non‐small cell lung cancer patients during first line therapy. Journal of Cachexia Sarcopenia and Muscle. 15(6). 2311–2322. 1 indexed citations

Groarke, John D., Jeffrey Crawford, Susie M. Collins, et al.. (2024). Ponsegromab for the Treatment of Cancer Cachexia. New England Journal of Medicine. 391(24). 2291–2303. 97 indexed citations breakdown →

Crawford, Jeffrey, Roberto A. Calle, Susie M. Collins, et al.. (2023). A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia. Clinical Cancer Research. 30(3). 489–497. 26 indexed citations

Crawford, Jeffrey, Shannon L. Lubaczewski, Yan Weng, et al.. (2023). Phase 2 study to assess the efficacy, safety, and tolerability of the GDF-15 inhibitor ponsegromab in patients with cancer cachexia.. Journal of Clinical Oncology. 41(16_suppl). TPS12147–TPS12147. 1 indexed citations

Crawford, Jeffrey, Roberto A. Calle, Susie M. Collins, et al.. (2023). Abstract CT108: First-in-patient study of the GDF-15 inhibitor ponsegromab in patients with cancer and cachexia: Safety, tolerability, and exploratory measures of efficacy. Cancer Research. 83(8_Supplement). CT108–CT108. 4 indexed citations

Crawford, Jeffrey, Shannon L. Lubaczewski, Magdalena Harrington, et al.. (2023). Abstract CT054: Phase 2 study to assess the efficacy, safety, and tolerability of the GDF-15 inhibitor ponsegromab in patients with cancer cachexia. Cancer Research. 83(8_Supplement). CT054–CT054. 1 indexed citations

Roeland, Eric, Sriram Yennu, Egidio Del Fabbro, et al.. (2021). 1696TiP Phase Ib study to assess the effect of PF-06946860 on appetite following subcutaneous administration in patients with anorexia and advanced cancer. Annals of Oncology. 32. S1185–S1185. 2 indexed citations

10.

Breen, Danna M., Hanna Kim, Donald Bennett, et al.. (2020). GDF-15 Neutralization Alleviates Platinum-Based Chemotherapy-Induced Emesis, Anorexia, and Weight Loss in Mice and Nonhuman Primates. Cell Metabolism. 32(6). 938–950.e6. 115 indexed citations

11.

Wu, Zhidan, Donald Bennett, Julia Brosnan, et al.. (2020). 2O Growth differentiation factor 15 (GDF-15) neutralization reverses cancer cachexia, restores physical performance and mitigates emesis associated with platinum-based chemotherapy. Annals of Oncology. 31. S245–S245. 4 indexed citations

12.

McDonnell, Aoibhinn, Susie M. Collins, Zahid Ali, et al.. (2018). Efficacy of the Nav1.7 blocker PF-05089771 in a randomised, placebo-controlled, double-blind clinical study in subjects with painful diabetic peripheral neuropathy. Pain. 159(8). 1465–1476. 111 indexed citations

13.

Winchester, Wendy J., Sophie Glatt, Kelly Conlon, et al.. (2014). Inhibition of TRPM8 Channels Reduces Pain in the Cold Pressor Test in Humans. Journal of Pharmacology and Experimental Therapeutics. 351(2). 259–269. 72 indexed citations

14.

Collins, Susie M., et al.. (2010). Cardiovascular safety assessments in the conscious telemetered dog: Utilisation of super-intervals to enhance statistical power. Journal of Pharmacological and Toxicological Methods. 62(1). 12–19. 36 indexed citations

15.

Aylott, Mike, et al.. (2010). Review of the statistical analysis of the dog telemetry study. Pharmaceutical Statistics. 10(3). 236–249. 22 indexed citations

16.

Ulrich, Kristina, et al.. (2008). Object orientated automated image analysis: quantitative and qualitative estimation of inflammation in mouse lung. Diagnostic Pathology. 3(Suppl 1). S16–S16. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact